Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis

OBJECTIVES: To examine whether treatment with anti‐tumour necrosis factor (TNF) α prevents loss of bone mineral density (BMD) at the spine and hip (generalised) and in the hands (local) of patients with rheumatoid arthritis, and to study the changes in markers of bone metabolism, including receptor...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Vis, M, Havaardsholm, E A, Haugeberg, G, Uhlig, T, Voskuyl, A E, van de Stadt, R J, Dijkmans, B A C, Woolf, A D, Kvien, T K, Lems, W F
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Group 2006
Schlagworte:
Extended Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC1798341/
https://ncbi.nlm.nih.gov/pubmed/16606653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2005.044198
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge